← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

CERS logoCerus Corporation(CERS)Earnings, Financials & Key Ratios

CERS•NASDAQ
$2.59
$519M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryRenal, dialysis, and blood purification
AboutCerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.Show more
  • Revenue$206M+14.3%
  • EBITDA-$34M-177.7%
  • Net Income-$16M+25.3%
  • EPS (Diluted)-0.08+25.5%
  • Gross Margin53.5%-3.1%
  • EBITDA Margin-16.66%-142.8%
  • Operating Margin-17.63%-123.5%
  • Net Margin-7.58%+34.7%
  • ROE-25.65%+32.4%
  • ROIC-19.7%-151.7%
  • Debt/Equity1.49-13.4%
  • Interest Coverage-4.36-225.6%
Technical→

CERS Key Insights

Cerus Corporation (CERS) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y profit CAGR of 23.6%
  • ✓Momentum leader: RS Rating 89 (top 11%)
  • ✓Strong 5Y sales CAGR of 17.5%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

CERS Price & Volume

Cerus Corporation (CERS) stock price & volume — 10-year historical chart

Loading chart...

CERS Growth Metrics

Cerus Corporation (CERS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years19.67%
5 Years17.53%
3 Years8.35%
TTM16.97%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM49.6%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM49.61%

Return on Capital

10 Years-42.06%
5 Years-24.31%
3 Years-21.59%
Last Year-28.14%

CERS Recent Earnings

Cerus Corporation (CERS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
Apr 30, 2026
EPS
$0.01
Est $0.03
+66.7%
Revenue
$60M
Est $56M
+7.6%
Q2 2026
Mar 2, 2026
EPS
$0.01
Est $0.01
+0.0%
Revenue
$65M
Est $62M
+4.5%
Q4 2025
Nov 6, 2025
EPS
$0.00
Est $0.02
+99.5%
Revenue
$53M
Est $59M
-11.1%
Q3 2025
Aug 5, 2025
EPS
$0.03
Est $0.02
-50.0%
Revenue
$52M
Est $54M
-3.4%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 30, 2026
$0.01vs $0.03+66.7%
$60Mvs $56M+7.6%
Q2 2026Mar 2, 2026
$0.01vs $0.01+0.0%
$65Mvs $62M+4.5%
Q4 2025Nov 6, 2025
$0.00vs $0.02+99.5%
$53Mvs $59M-11.1%
Q3 2025Aug 5, 2025
$0.03vs $0.02-50.0%
$52Mvs $54M-3.4%
Based on last 12 quarters of dataView full earnings history →

CERS Peer Comparison

Cerus Corporation (CERS) competitors in Renal, dialysis, and blood purification — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
TXG logoTXG10x Genomics, Inc.Direct Competitor2.93B22.74-64.975.25%-6.77%-5.69%0.20
BLFS logoBLFSBioLife Solutions, Inc.Direct Competitor1.05B21.75-8716.97%-12.61%-3.26%0.03
NTRA logoNTRANatera, Inc.Direct Competitor29.58B215.09-140.5856.75%-14.61%-24.69%0.16
AGEN logoAGENAgenus Inc.Direct Competitor137.4M3.89-1144.1210.37%0.1%
HAE logoHAEHaemonetics CorporationProduct Competitor2.45B52.6415.903.95%13.31%20.26%1.49
TER logoTERTeradyne, Inc.Product Competitor59.95B382.91110.0313.13%22.55%29.72%0.12
ISRG logoISRGIntuitive Surgical, Inc.Product Competitor160.44B451.7357.4020.51%28.15%16.89%0.02
GMED logoGMEDGlobus Medical, Inc.Product Competitor12.07B89.2222.7616.65%18.3%12.4%0.03

Compare CERS vs Peers

Cerus Corporation (CERS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs TXG

Most directly comparable listed peer for CERS.

Scale Benchmark

vs ISRG

Larger-name benchmark to compare CERS against a more recognizable public peer.

Peer Set

Compare Top 5

vs TXG, BLFS, NTRA, AGEN

CERS Income Statement

Cerus Corporation (CERS) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue43.57M60.91M74.65M91.92M130.86M162.05M156.37M180.27M206.13M216.56M
Revenue Growth %17.17%39.8%22.56%23.14%42.36%23.83%-3.51%15.29%14.35%16.97%
Cost of Goods Sold22.53M31.63M33.42M41.16M63.48M74.95M69.97M80.75M95.84M101.8M
COGS % of Revenue51.71%51.94%44.77%44.77%48.51%46.25%44.75%44.79%46.5%-
Gross Profit
21.04M▲ 0%
29.27M▲ 39.2%
41.23M▲ 40.8%
50.76M▲ 23.1%
67.38M▲ 32.7%
87.09M▲ 29.3%
86.4M▼ 0.8%
99.52M▲ 15.2%
110.29M▲ 10.8%
114.76M▲ 0%
Gross Margin %48.29%48.06%55.23%55.23%51.49%53.75%55.25%55.21%53.5%52.99%
Gross Profit Growth %24.57%39.15%40.84%23.12%32.74%29.25%-0.8%15.19%10.82%-
Operating Expenses78.57M84.26M107.46M109.1M116.32M121.17M116.45M113.75M146.63M138.68M
OpEx % of Revenue180.33%138.34%143.95%118.69%88.89%74.78%74.47%63.1%71.14%-
Selling, General & Admin52.41M56.84M66.2M67.02M81.29M83.33M75.52M75.89M80.91M80.58M
SG&A % of Revenue120.3%93.32%88.69%72.91%62.12%51.43%48.29%42.1%39.25%-
Research & Development33.71M42.56M60.38M64.41M63.69M64.11M67.64M58.91M65.72M65.65M
R&D % of Revenue77.37%69.88%80.88%70.07%48.67%39.56%43.26%32.68%31.88%-
Other Operating Expenses3.86M1.75M-19.13M-22.33M-28.66M-26.27M-26.7M-21.05M0-1000K
Operating Income
-57.53M▲ 0%
-54.99M▲ 4.4%
-66.23M▼ 20.4%
-58.33M▲ 11.9%
-48.94M▲ 16.1%
-34.08M▲ 30.4%
-30.05M▲ 11.8%
-14.22M▲ 52.7%
-36.35M▼ 155.5%
-17.69M▲ 0%
Operating Margin %-132.05%-90.28%-88.72%-63.46%-37.4%-21.03%-19.22%-7.89%-17.63%-8.17%
Operating Income Growth %6.37%4.42%-20.44%11.92%16.11%30.36%11.82%52.67%-155.51%-
EBITDA-55.72M-53.54M-63.82M-53.88M-45.79M-31.1M-27.45M-12.37M-34.35M-15.86M
EBITDA Margin %-127.89%-87.91%-85.5%-58.61%-34.99%-19.19%-17.56%-6.86%-16.66%-7.32%
EBITDA Growth %6.56%3.91%-19.2%15.58%15.02%32.08%11.71%54.94%-177.66%1.99%
D&A (Non-Cash Add-back)1.81M1.45M2.4M4.46M3.15M2.98M2.6M1.85M2M1.83M
EBIT-53.68M-53.33M-67.02M-55.83M-49.13M-36.51M-28.94M-11.88M-36.35M-16.39M
Net Interest Income-3.02M-4.01M-6.07M-3.75M-4.92M-5.83M-8.39M-8.88M-8.34M-6.23M
Interest Income0000000000
Interest Expense3.02M4.01M6.07M3.75M4.92M5.83M8.39M8.88M8.34M6.23M
Other Income/Expense832K-2.35M-4.75M-1.24M-5.12M-8.26M-7.27M-6.53M21.06M8.5M
Pretax Income
-56.7M▲ 0%
-57.34M▼ 1.1%
-70.98M▼ 23.8%
-59.57M▲ 16.1%
-54.06M▲ 9.3%
-42.34M▲ 21.7%
-37.32M▲ 11.8%
-20.76M▲ 44.4%
-15.28M▲ 26.4%
-9.2M▲ 0%
Pretax Margin %-130.14%-94.13%-95.09%-64.81%-41.31%-26.13%-23.87%-11.51%-7.41%-4.25%
Income Tax3.89M229K263K284K319K488K325K205K354K371K
Effective Tax Rate %-6.86%-0.4%-0.37%-0.48%-0.59%-1.15%-0.87%-0.99%-2.32%-4.03%
Net Income
-60.59M▲ 0%
-57.56M▲ 5.0%
-71.24M▼ 23.8%
-59.86M▲ 16.0%
-54.37M▲ 9.2%
-42.78M▲ 21.3%
-37.49M▲ 12.4%
-20.92M▲ 44.2%
-15.63M▲ 25.3%
-9.55M▲ 0%
Net Margin %-139.06%-94.51%-95.44%-65.12%-41.55%-26.4%-23.97%-11.6%-7.58%-4.41%
Net Income Growth %3.69%4.99%-23.76%15.98%9.16%21.32%12.37%44.2%25.29%49.6%
Net Income (Continuing)-60.59M-57.56M-71.24M-59.86M-54.38M-42.83M-37.65M-20.96M-15.64M-9.56M
Discontinued Operations0000000000
Minority Interest0000998K952K794K751K741K733K
EPS (Diluted)
-0.56▲ 0%
-0.44▲ 21.4%
-0.51▼ 15.9%
-0.37▲ 27.5%
-0.32▲ 13.5%
-0.24▲ 25.0%
-0.21▲ 12.5%
-0.11▲ 47.6%
-0.08▲ 25.5%
-0.05▲ 0%
EPS Growth %9.68%21.43%-15.91%27.45%13.51%25%12.5%47.62%25.45%49.61%
EPS (Basic)-0.56-0.44-0.51-0.37-0.32-0.24-0.21-0.11-0.08-
Diluted Shares Outstanding108.22M131.66M139.83M163.95M171.28M176.54M180.27M184.56M190.59M194.14M
Basic Shares Outstanding108.19M130.83M139.83M163.95M171.28M176.54M180.27M184.56M190.59M194.14M
Dividend Payout Ratio----------

CERS Balance Sheet

Cerus Corporation (CERS) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets89.9M146.9M128.11M183.43M187.1M170.14M144.44M152.02M174.38M175.34M
Cash & Short-Term Investments60.7M117.58M85.72M133.59M129.36M102.15M65.85M80.45M82.88M80.42M
Cash Only13.68M28.86M34.99M36.59M48.76M35.59M11.65M20.27M19.96M27.85M
Short-Term Investments47.01M88.72M50.73M97M80.6M66.57M54.2M60.19M62.92M52.58M
Accounts Receivable12.41M8.75M16.88M21.17M25.13M34.43M35.5M29.78M30.37M29.32M
Days Sales Outstanding104.0152.4582.5584.0570.0977.5482.8760.2953.7850.93
Inventory14.46M13.54M19.49M23.25M26.79M29M39.87M38.15M56.1M61.12M
Days Inventory Outstanding234.2156.22212.87206.23154.07141.23207.98172.45213.65201.59
Other Current Assets2.33M00004.56M3.22M3.64M5.03M4.47M
Total Non-Current Assets8.35M16.56M37.43M37.98M50.4M47.95M53.31M48.9M47.48M47.57M
Property, Plant & Equipment2.12M8.13M29.02M26.99M25.18M23.48M19.35M15.54M19.33M18.7M
Fixed Asset Turnover20.56x7.49x2.57x3.41x5.20x6.90x8.08x11.60x10.66x12.69x
Goodwill1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M
Intangible Assets536K334K132K0000000
Long-Term Investments247K2.73M00000001.14M
Other Non-Current Assets4.38M6.78M6.96M9.68M23.9M23.15M32.64M32.04M26.83M112.99M
Total Assets
98.24M▲ 0%
163.46M▲ 66.4%
165.53M▲ 1.3%
221.41M▲ 33.8%
237.5M▲ 7.3%
218.09M▼ 8.2%
197.75M▼ 9.3%
200.92M▲ 1.6%
221.86M▲ 10.4%
222.91M▲ 0%
Asset Turnover0.44x0.37x0.45x0.42x0.55x0.74x0.79x0.90x0.93x0.99x
Asset Growth %-5.06%66.38%1.27%33.76%7.26%-8.17%-9.33%1.6%10.42%46.62%
Total Current Liabilities23.13M52.68M50.34M59.97M78.56M117.06M67.52M63.61M100.8M107.38M
Accounts Payable10.97M18.59M22.18M24.21M35.61M33M23.84M21.7M28.01M0
Days Payables Outstanding177.78214.55242.3214.73204.76160.71124.3898.07106.6675.29
Short-Term Debt07.86M5.02M8.52M14.7M56.16M20M19.3M46.25M55.54M
Deferred Revenue (Current)445K498K570K577K673K589K2M1.4M1.27M7.49M
Other Current Liabilities4.34M14.96M12.7M16M18.51M17.58M11.82M11.94M25.27M50.12M
Current Ratio3.89x2.79x2.55x3.06x2.38x1.45x2.14x2.39x1.73x1.73x
Quick Ratio3.26x2.53x2.16x2.67x2.04x1.21x1.55x1.79x1.17x1.17x
Cash Conversion Cycle160.43-5.8953.1175.5419.458.07166.47134.67160.77177.23
Total Non-Current Liabilities36.17M26.26M58.15M57.63M73.33M32.47M76.78M80.41M56.09M47.24M
Long-Term Debt29.8M22.01M39.41M39.59M54.72M13.64M59.8M64.86M40.55M9.38M
Capital Lease Obligations0018.41M16.87M16.26M15.33M13.75M11.66M10.15M32.23M
Deferred Tax Liabilities-100K000000000
Other Non-Current Liabilities6.38M4.25M327K1.17M2.34M3.5M3.24M3.89M5.39M52.85M
Total Liabilities59.3M78.94M108.48M117.61M151.88M149.53M144.3M144.02M156.89M154.62M
Total Debt29.8M29.87M64.45M66.89M87.59M87.24M96M98.1M96.95M64.92M
Net Debt16.11M1.01M29.46M30.3M38.83M51.65M84.35M77.83M76.98M37.07M
Debt / Equity0.77x0.35x1.13x0.64x1.02x1.27x1.80x1.72x1.49x1.49x
Debt / EBITDA----------4.09x
Net Debt / EBITDA----------2.34x
Interest Coverage-17.76x-13.31x-11.05x-14.90x-9.98x-6.26x-3.45x-1.34x-4.36x-2.63x
Total Equity
38.94M▲ 0%
84.52M▲ 117.0%
57.05M▼ 32.5%
103.81M▲ 81.9%
85.62M▼ 17.5%
68.56M▼ 19.9%
53.44M▼ 22.1%
56.9M▲ 6.5%
64.97M▲ 14.2%
68.29M▲ 0%
Equity Growth %-32.61%117.05%-32.5%81.95%-17.52%-19.92%-22.05%6.46%14.18%61.86%
Book Value per Share0.360.640.410.630.500.390.300.310.340.35
Total Shareholders' Equity38.94M84.52M57.05M103.81M84.62M67.61M52.65M56.15M64.22M68.29M
Common Stock115K136K144K168K174K177K181K186K192K200K
Retained Earnings-721.3M-778.87M-850.11M-909.97M-964.34M-1.01B-1.04B-1.07B-1.08B-1.08B
Treasury Stock0000000000
Accumulated OCI-97K-281K114K674K-149K-2.79M-1.27M-400K-156K-323K
Minority Interest0000998K952K794K751K741K733K

CERS Cash Flow Statement

Cerus Corporation (CERS) cash flow — operating, investing & free cash flow history

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations-52.23M-31.25M-65.5M-41.81M-33.92M-25.61M-43.17M11.36M11.36M11.36M
Operating CF Margin %-119.89%-51.3%-87.74%-45.49%-25.92%-15.81%-27.61%6.3%5.51%-
Operating CF Growth %2.42%40.18%-109.62%36.17%18.87%24.49%-68.53%126.31%0%-998.1%
Net Income-60.59M-57.56M-71.24M-59.86M-54.38M-42.83M-37.49M-20.96M-15.63M-9.55M
Depreciation & Amortization1.81M1.45M2.4M3.11M3.15M2.98M2.6M1.85M1.85M2M
Stock-Based Compensation9.36M10.39M13.31M18.03M23.57M24.46M20.27M22.87M22.87M21.14M
Deferred Taxes3.71M4K00462K00000
Other Non-Cash Items-2.92M1.25M2.33M1.11M2.67M5.82M3.49M2.37M9.09M1.76M
Working Capital Changes-3.61M13.22M-12.3M-4.2M-9.4M-16.05M-32.03M5.23M-6.83M-12.7M
Change in Receivables-5.55M3.66M-8.07M-4.13M-4.21M-9.2M-1.1M5.5M-396K-3.19M
Change in Inventory-2.09M806K-6.04M-4.03M-19.61M-1.77M-14.95M7.03M-14.68M-14.16M
Change in Payables2.49M5.68M4.94M1.98M12.2M-4.91M-7.33M-1.48M5.72M4.83M
Cash from Investing421K-43.85M28.18M-49.56M12.69M8.46M8.62M-8.13M-8.13M4.88M
Capital Expenditures-353K-1.14M-8.94M-1.61M-910K-2M-4.6M-2.84M-2.84M-2.96M
CapEx % of Revenue0.81%1.88%11.97%1.76%0.7%1.23%2.94%1.57%1.38%-
Acquisitions-3.47M000910K-10.46M0000
Investments----------
Other Investing3.47M-42.7M00-910K10.46M0001.97M
Cash from Financing43M92.75M43.49M91.78M34.29M4.19M10.67M4.96M4.96M352K
Debt Issued (Net)10.38M-133K13.35M3.5M21.18M212K9.92M4.3M-329K128K
Equity Issued (Net)30.2M85.04M26.93M76.53M2.74M-104K-175K0560K263K
Dividends Paid0000000000
Share Repurchases00000-104K-175K00263K
Other Financing2.43M7.85M3.21M11.75M10.37M4.08M925K667K4.73M-39K
Net Change in Cash
-8.81M▲ 0%
17.66M▲ 300.3%
5.83M▼ 67.0%
1.48M▼ 74.6%
12.14M▲ 719.2%
-13.69M▼ 212.7%
-24M▼ 75.4%
8M▲ 133.3%
8M▲ 0.0%
8.4M▲ 0%
Free Cash Flow
-52.59M▲ 0%
-32.39M▲ 38.4%
-74.43M▼ 129.8%
-43.43M▲ 41.7%
-34.83M▲ 19.8%
-27.61M▲ 20.7%
-47.77M▼ 73.0%
8.52M▲ 117.8%
8.52M▲ 0.0%
-1.22M▲ 0%
FCF Margin %-120.7%-53.18%-99.71%-47.24%-26.62%-17.04%-30.55%4.73%4.13%-0.56%
FCF Growth %2.78%38.41%-129.81%41.66%19.79%20.72%-72.97%117.84%0%-118.16%
FCF per Share-0.49-0.25-0.53-0.26-0.20-0.16-0.260.050.040.04
FCF Conversion (FCF/Net Income)0.86x0.54x0.92x0.70x0.62x0.60x1.15x-0.54x-0.73x0.13x
Interest Paid2.03M2.73M3.08M3.27M4.18M5.1M9.21M000
Taxes Paid160K254K229K265K278K270K322K356K00

CERS Key Ratios

Cerus Corporation (CERS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)-125.27%-93.25%-100.65%-74.42%-57.41%-55.49%-61.45%-37.92%-25.65%-15.18%
Return on Invested Capital (ROIC)-78.7%-58.67%-57.74%-39.66%-28.39%-20.9%-17.47%-7.83%-19.7%-19.7%
Gross Margin48.29%48.06%55.23%55.23%51.49%53.75%55.25%55.21%53.5%52.99%
Net Margin-139.06%-94.51%-95.44%-65.12%-41.55%-26.4%-23.97%-11.6%-7.58%-4.41%
Debt / Equity0.77x0.35x1.13x0.64x1.02x1.27x1.80x1.72x1.49x1.49x
Interest Coverage-17.76x-13.31x-11.05x-14.90x-9.98x-6.26x-3.45x-1.34x-4.36x-2.63x
FCF Conversion0.86x0.54x0.92x0.70x0.62x0.60x1.15x-0.54x-0.73x0.13x
Revenue Growth17.17%39.8%22.56%23.14%42.36%23.83%-3.51%15.29%14.35%16.97%

CERS SEC Filings & Documents

Cerus Corporation (CERS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 30, 2026·SEC

Material company update

Apr 21, 2026·SEC

Material company update

Mar 16, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 2, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Mar 5, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 30, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 5, 2025·SEC

CERS Frequently Asked Questions

Cerus Corporation (CERS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Cerus Corporation (CERS) reported $216.6M in revenue for fiscal year 2025. This represents a 3038% increase from $6.9M in 1997.

Cerus Corporation (CERS) grew revenue by 14.3% over the past year. This is steady growth.

Cerus Corporation (CERS) reported a net loss of $9.6M for fiscal year 2025.

Dividend & Returns

Cerus Corporation (CERS) has a return on equity (ROE) of -25.6%. Negative ROE indicates the company is unprofitable.

Cerus Corporation (CERS) had negative free cash flow of $1.2M in fiscal year 2025, likely due to heavy capital investments.

Explore More CERS

Cerus Corporation (CERS) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.